Orchiectomy and Radical Prostatectomy for Localized Castration-Sensitive Prostate Cancer
For localized, hormone-sensitive prostate cancer, radical prostatectomy is a recommended standard treatment option, but orchiectomy (surgical castration) is NOT recommended as primary therapy. Orchiectomy is reserved for metastatic disease or specific palliative situations, not for localized disease where curative intent is appropriate.
Treatment Recommendations Based on Risk Stratification
The appropriate treatment depends critically on risk classification:
Low-Risk Disease
- Radical prostatectomy or radiotherapy are standard curative options 1
- Active surveillance is also appropriate for select patients with low-risk disease and life expectancy >10 years 1, 2
- Watchful waiting with delayed hormone therapy is an option for men not suitable for or unwilling to have radical treatment 2
Intermediate-Risk Disease
- Radical prostatectomy or radiotherapy plus ADT are recommended as standard treatment options 1
- For favorable intermediate-risk disease, radiation alone may be considered, though the evidence is less robust than combination therapy 1
- Active surveillance may be offered to select patients with favorable intermediate-risk disease, but carries higher risk of metastases compared to definitive treatment 1
High-Risk Disease
- Radical prostatectomy or radiotherapy plus ADT (for at least 2 years) are the standard treatment options 1, 3
- Active surveillance is NOT recommended for high-risk disease 1
- Watchful waiting should only be considered in asymptomatic men with limited life expectancy (≤5 years) 1
Why Orchiectomy is NOT Appropriate for Localized Disease
Primary ADT (including orchiectomy) is not recommended for patients with localized prostate cancer unless the patient has both limited life expectancy AND local symptoms 1. The evidence is clear:
- Orchiectomy and other forms of castration are reserved for metastatic or recurrent androgen-sensitive prostate cancer where ADT is considered the most appropriate initial intervention 4
- For localized disease, the goal is cure, not palliation 4
- Primary ADT alone is not recommended as standard initial treatment of non-metastatic disease 2
Radical Prostatectomy: The Evidence
The strongest evidence supporting radical prostatectomy comes from randomized controlled trials:
- The SPCG-4 trial demonstrated that radical prostatectomy reduced prostate cancer-specific mortality compared to watchful waiting (14.6% vs 20.7% at 18 years, p=0.001) 2, 3
- All-cause mortality also favored surgery (46.1% vs 52.7%, RR 0.75) 1
- In high-risk patients undergoing surgery, prostate cancer-specific death was significantly lower (9.1% vs 17.5% for observation) 1
Common Pitfalls to Avoid
- Do not confuse localized disease with metastatic disease: Orchiectomy is appropriate for metastatic disease but represents undertreatment for localized disease where cure is possible
- Risk stratification is mandatory: Treatment selection must be based on PSA, Gleason score, and clinical stage 1, 2
- Consider patient factors: Age, comorbidities, and life expectancy significantly impact treatment selection—older men experience higher rates of erectile dysfunction and urinary incontinence after prostatectomy 5
- Neoadjuvant ADT is NOT recommended before radical prostatectomy outside clinical trials 5
Algorithmic Approach
- Confirm localized disease through appropriate staging (bone scan and cross-sectional imaging for intermediate/high-risk) 1
- Stratify risk using PSA, Gleason score, and clinical stage
- Assess patient factors: life expectancy, comorbidities, patient preferences
- Select treatment:
- Life expectancy >10 years + low/intermediate risk → Radical prostatectomy OR radiotherapy
- Life expectancy >10 years + high risk → Radical prostatectomy OR radiotherapy + ADT (2-3 years)
- Life expectancy ≤5 years → Watchful waiting
- Reserve orchiectomy only for metastatic disease or palliative situations with limited life expectancy and local symptoms